Comparative Pharmacology
Head-to-head clinical analysis: LUMI SPORYN versus MAFENIDE ACETATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LUMI SPORYN versus MAFENIDE ACETATE.
LUMI-SPORYN vs MAFENIDE ACETATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
LUMI-SPORYN is a synthetic antimicrobial that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), specifically PBP3, leading to impaired cross-linking of peptidoglycan and osmotic lysis. It also exhibits concentration-dependent bactericidal activity.
Mafenide acetate is a sulfonamide antibiotic that inhibits bacterial folic acid synthesis by competitively antagonizing para-aminobenzoic acid (PABA), thereby preventing bacterial growth. It has broad-spectrum activity against gram-negative and gram-positive organisms, including Pseudomonas aeruginosa.
1000 mg IV every 8 hours over 1 hour for adults with normal renal function.
Apply topically as a thin layer to affected areas once or twice daily. The dosage form is an 11.1% cream or solution. The cream is applied using a sterile gloved hand; the solution is applied with a sterile spray or brush.
None Documented
None Documented
6-8 hours; prolonged to 15-30 hours in severe renal impairment (CrCl <30 mL/min)
Approximately 45 minutes (range 30-60 minutes) for the parent compound; the metabolite p-CBS has a longer half-life of about 4 hours.
Renal 70-80% unchanged, biliary/fecal 20-30%
Renal: approximately 80% excreted unchanged in urine; the remainder is metabolized to p-carboxybenzene sulfonamide (p-CBS) which is also renally excreted.
Category C
Category C
Topical Antibiotic
Topical Antibiotic